Brunswick Corp (BC) Stock News

New CNBC Generation Lab poll shows almost half of 18- to 34-year-olds see democratic socialism positively and nearly 80% see the U.S. economy negatively.

New CEO Josh D'Amaro has said his strategy for continued growth at Disney is centered around storytelling, intellectual property and technology.

Schall, Brown & Schwartz LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged violations of securities laws. The lawsuit claims the company made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to disclose known market headwinds in the pen needle sector. The class period runs from November 25, 2025 to May 4, 2026, with a deadline of August 17, 2026 for investors to participate.

The Rosen Law Firm is investigating potential securities claims against Barclays PLC following Reuters reports of the company's £600 million exposure to failed UK mortgage lender Market Financial Solutions Ltd. Barclays' stock fell 3.99% on February 27, 2026, and an additional 2.3% on March 2, 2026, following the disclosure. The firm is preparing a class action lawsuit to recover investor losses.

Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Barclays PLC and The Ensign Group, Inc. The investigation into Barclays stems from allegations of materially misleading business information disclosed to investors, particularly regarding a £600 million exposure to failed British mortgage lender Market Financial Solutions Ltd, which caused Barclays' stock to decline 3.99% on February 27, 2026.

Hagens Berman is investigating Embecta Corp. (NASDAQ: EMBC) for allegedly misleading investors about the stability of its insulin pen needle business. The company claimed its pen needle portfolio was 'stable' and 'resilient' while experiencing significant competitive share loss and market volume softness. On May 5, 2026, Embecta revealed massive revenue declines, slashed full-year 2026 adjusted EPS guidance by 43%, and cut its quarterly dividend by 93%, causing the stock to plummet 57.8% in a single trading day. Investors with substantial losses during the class period (Nov. 25, 2025 – May 4, 2026) are encouraged to participate in the lawsuit with a lead plaintiff deadline of August 17, 2026.

Class action lawsuits have been filed against four publicly-traded companies alleging securities fraud. Erasca faces allegations regarding misleading preclinical data comparisons; Via Transportation failed to disclose declining ARR and regulatory issues; Embecta misrepresented guidance and segment weakness; and Zillow mischaracterized its Redfin agreement and downplayed antitrust risks. Investors have until mid-August 2026 to file lead plaintiff motions.

The Rosen Law Firm is investigating potential securities claims against Barclays PLC following allegations of materially misleading business information. The investigation was triggered by Reuters reporting on February 27, 2026, that Barclays had a £600 million exposure to the collapsed UK mortgage lender Market Financial Solutions Ltd. Barclays' stock fell 3.99% on February 27 and 2.3% on March 2, 2026, following the news. The firm is preparing a class action lawsuit to recover investor losses.

Embecta Corp. (NASDAQ: EMBC) faces a securities class action lawsuit for allegedly misleading investors about fiscal year 2026 performance. The company promised flat-to-down-2% revenue and $2.80-$3.00 EPS but delivered a 17.4% revenue collapse and slashed earnings guidance by nearly half. The stock plummeted 57.8% on May 5, 2026, from $9.25 to $3.90. The lawsuit alleges management knew of U.S. market weakness when reaffirming guidance between November 25, 2025 and February 5, 2026.

Hagens Berman is investigating Embecta Corp. for alleged securities law violations, claiming the company misrepresented the stability of its insulin pen needle business. On May 5, 2026, Embecta revealed significant revenue decline, slashed full-year EPS guidance by 43%, and cut its quarterly dividend by 93%, causing the stock to plummet 57.8% in a single trading day. The class action lawsuit covers the period from November 25, 2025 to May 4, 2026, with a lead plaintiff deadline of August 17, 2026.

Schall, Brown & Schwartz LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged violations of securities laws. The lawsuit claims the company made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to disclose known market headwinds in the pen needle sector. The class period runs from November 25, 2025 to May 4, 2026, with a deadline of August 17, 2026 for shareholders to participate.

Emirates NBD Bank to acquire retail banking business of HSBC Egypt  Reuters

Rosen Law Firm is notifying Embecta Corp. investors who purchased stock between November 25, 2025 and May 4, 2026 about a securities class action lawsuit. The lawsuit alleges that Embecta made false and misleading statements regarding its fiscal results and guidance, specifically touting its pen needle business as 'incredibly resolute' before missing expectations and cutting 2026 guidance. Investors with losses exceeding $100,000 are encouraged to join the class action before the August 17, 2026 lead plaintiff deadline.

Hagens Berman is investigating Embecta Corp. for alleged securities law violations, claiming the company misrepresented the stability of its insulin pen needle business. Embecta's stock plummeted 57.8% after revealing significant revenue decline, slashing full-year EPS guidance by 43% and cutting its quarterly dividend by 93%. The class action lawsuit covers the period from November 25, 2025 to May 4, 2026, with a lead plaintiff deadline of August 17, 2026.

The next iteration of the streaming wars is likely to be about aggregating content on the biggest existing platforms.

Rosen Law Firm is investigating potential securities claims against Barclays PLC following allegations of materially misleading business information. The investigation was triggered by reports of Barclays' £600 million exposure to failed UK mortgage lender Market Financial Solutions Ltd, which caused Barclays' stock to decline 3.99% on February 27, 2026, and an additional 2.3% on March 2, 2026. Investors who purchased Barclays securities may be eligible to join a class action lawsuit.

Rosen Law Firm is reminding Embecta Corp. investors who purchased stock between November 25, 2025 and May 4, 2026 of an August 17, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Embecta made false and misleading statements about its fiscal results and guidance, particularly regarding its pen needle business, which it described as 'incredibly resolute' before missing expectations and cutting 2026 guidance.

HSBC leverages up to 19 times deposits, capturing $5.5 billion in Indian Forex, outpacing rivals like Standard Chartered.

The article compares two unprofitable but rapidly growing companies: Planet Labs PBC, which operates 200+ satellites for Earth imaging, and Snowflake, a cloud data platform for AI analytics. Both face different competitive pressures and risk profiles. Planet Labs has lower valuation multiples but higher government revenue concentration, while Snowflake benefits from platform-agnostic positioning in the AI boom. The author gives a slight edge to Planet Labs for its stronger competitive moat, though neither is guaranteed long-term success.

Shareholder class action lawsuits have been filed against Embecta Corp. and Via Transportation Inc., with allegations of false statements and failure to disclose segment weakness and revenue guidance disruptions. Additionally, Holzer & Holzer, LLC announced an investigation into ADTRAN Holdings Inc. regarding potential federal securities law violations. Investors who suffered losses during the relevant periods are encouraged to contact the law firm.

Temenos has been recognized in CNBC's World's Top Fintech Companies 2026 list for the third consecutive year in the Enterprise Fintech category. The selection was based on analysis of 3,500 companies worldwide. Temenos serves over 950 core banking clients and 600 digital clients globally, offering cloud-native banking solutions.

HSBC initiated coverage of SpaceX with a Hold rating and $115 price target, below the company's $135 IPO price. Despite applying a 2x premium for CEO Elon Musk's innovation track record, the bank concluded the stock's current valuation already reflects much of its long-term growth potential. SpaceX shares closed at $115.07, roughly 50% below their post-IPO high of $225.64, trading at over 75x sales with no profitability yet.

The Rosen Law Firm is investigating potential securities claims against Barclays PLC following allegations of materially misleading business information. The investigation was triggered by Reuters reporting on Barclays' £600 million exposure to failed UK mortgage lender Market Financial Solutions Ltd, which caused Barclays' stock to decline 3.99% on February 27, 2026, and an additional 2.3% on March 2, 2026. The firm is preparing a class action lawsuit to recover investor losses.

Oportun, a mission-driven financial services company, has been recognized on CNBC's World's Top Fintech Companies 2026 list for the third consecutive year in the Wealth Technology category. The recognition highlights the company's intelligent borrowing, savings, and budgeting tools designed to help members improve their financial well-being. Since inception, Oportun has provided over $22.3 billion in responsible credit and helped members save more than $2.5 billion in interest and fees.

Embecta Corp. faces a securities fraud class action lawsuit after its stock plummeted 57.8% on May 5, 2026, when the company revealed disappointing Q2 results and admitted to significant market softness in insulin pens and pen needles. Investors allege the company misrepresented the strength of its insulin pen portfolio prior to the announcement. The lead plaintiff deadline is August 17, 2026.

Genmab and AbbVie announced that the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab (a T-cell engaging bispecific antibody) failed to meet its primary endpoint of overall survival in the United States when compared to standard chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma. Despite the trial failure, epcoritamab remains approved under accelerated approval and the companies continue to evaluate the therapy in other clinical programs.

Rosen Law Firm is reminding investors who purchased Embecta Corp. common stock between November 25, 2025 and May 4, 2026 of the August 17, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Embecta made false and misleading statements about its fiscal results and guidance, particularly regarding its pen needle business, which it described as 'incredibly resolute' before missing expectations and cutting 2026 guidance.

Northrim BanCorp announced it will acquire PBCO Financial Corporation (People's Bank of Commerce) in an all-stock transaction valued at approximately $167.3 million ($32.36 per share). The merger marks Northrim's first out-of-state expansion, extending its community banking operations into Southern Oregon and the Willamette Valley. The combined entity will have over $4 billion in assets, with closing expected in Q4 2026 or early Q1 2027.

Netflix filed SEC documents for routine $1 billion debt refinancing, not a major acquisition. The company walked away from bidding on Warner Bros. Discovery after Paramount Skydance offered $111 billion, and also passed on acquiring Roku. Instead of pursuing legacy content libraries, Netflix appears focused on diversifying into gaming, physical entertainment spaces, and building an entertainment empire from scratch.

Greater Victoria's population growth slowed significantly to 0.7% in 2025, adding only 3,129 residents to reach 445,090 people—the smallest increase since 2011. International migration declined 83.6% year-over-year, while housing affordability remains a major challenge with single-family home prices at $1.16 million. Apartment rents surged 7% annually, with larger units jumping 20.8%, as the housing market experienced slower sales activity in the first half of 2026.